News stories about Valeritas Holdings (NASDAQ:VLRX) have trended somewhat positive on Wednesday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Valeritas Holdings earned a coverage optimism score of 0.08 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.4926751320818 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Several equities analysts have recently weighed in on VLRX shares. Wedbush started coverage on Valeritas Holdings in a report on Monday, July 10th. They issued an “outperform” rating and a $12.00 price objective for the company. ValuEngine cut Valeritas Holdings from a “sell” rating to a “strong sell” rating in a report on Wednesday, July 19th.
Valeritas Holdings (NASDAQ:VLRX) last posted its earnings results on Friday, August 11th. The company reported ($1.83) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.87) by $0.04. The business had revenue of $4.79 million during the quarter, compared to analyst estimates of $5.11 million.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://sportsperspectives.com/2017/11/01/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-valeritas-holdings-vlrx-share-price.html.
About Valeritas Holdings
Valeritas, Inc is a United States-based company, which is engaged in developing and commercializing treatment solutions that contribute to clinical outcomes for patients. The Company’s portfolio includes V-Go disposable insulin delivery device, which is distributed through retail pharmacy. Its V-Go delivers insulin at a continuous preset basal rate and bolus dosing for adults with Type 2 diabetes requiring insulin.
Receive News & Ratings for Valeritas Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.